Episode 104: Metastatic Gastric and GOJ Cancers

With ASCO upon us, Michael and Josh squeeze one more episode of their regular schedule to bring you an important update on gastric cancer. For context, the 5 year survival rate for metastatic gastric cancer is 6%, similar to that of pancreatic cancer. Despite improvement in survival due to the addition of nivolumab to chemotherapy (Checkmate 64), few therapies have significantly changed it's overall prognosis.

This week Michael and Josh explore the addition of a LAG-3 inhibitor (relatlimab) to the SOC nivolumab and chemotherapy to see if gastric cancers fortune may change. Synergistic evidence has been seen in melanoma, but melanoma has a completely different biology.. Michael engages with Keynote-811, the addition of trastuzumab to SOC chemotherapy for hER2 positive metastatic gastric/GOJ cancer. Is this HER2 antibody strong enough to stop this cancers march?

Tune in today, and for the foreseeable future and Josh and Michael go where no podcaster has gone before--->

Links to articles discussed in this episode (subscription may be required):

Relativity 060: Link

Keynote 811: Link